Pfizer Articles
IQWiG re-assessments come up with same view for saxagliptin and different for crizotinib
14 May 2013
New York parents charge Pfizer for concealing true risks of birth defects linked to Zoloft
7 May 2013
World's first long-lasting hemophilia therapies will see Biogen move ahead of Pfizer and Baxter
23 April 2013
Mylan delivers "one pill once a day" ARV in South Africa; Cipla Debuts first Enbrel biosimilar
17 April 2013
Adult vaccines market controlled by GSK and Merck
15 April 2013
US pulmonologists view refractory asthma patient treatment with biosimilar Xolair by end-2018
10 April 2013
Conditional EU approval for Pfizer's CML drug Bosulif
28 March 2013
Synta's ganetespib shows potency against ALK-positive lung cancer and overcomes crizotinib resistance
27 March 2013
Advantages of Tivopath over currently used kidney cancer therapies seen by thought leaders
27 March 2013
Preliminary NICE guidance negative on Pfizer's Xalkori for lung cancer; backs Colobreathe and Tobi Podhaler for CF
27 March 2013
BioTrends views Xeljanz and Zytiga prescribing in USA
26 March 2013
Regulatory briefs on Bayer's Stivarga, Boehringer/Lilly's empagliflozin and Pfizer's Xeljanz
26 March 2013
$30 billion of fresh opportunities for Rx-to-OTC switch in USA
19 February 2013
Study finds "Big Pharma" fails at self-policing ED drug advertising
18 February 2013
Cipla prevails in Sutent patent dispute with Pfizer; puts hold on Cipla Medpro deal
12 February 2013
New briefs on Pfizer interest in Protalix; Novo Nordisk warning letter; Hemispherx' Ampligen; and Idenix' hep C program
6 February 2013
Pfizer prevails in Rapamune patent dispute with Watson
1 February 2013
US and European oncologists see novel chemotherapies as best hope for soft tissue sarcoma
30 January 2013
New Zealand approves funding of sildenafil for Raynaud's phenomenon and bosentan for children with PAH
28 January 2013
FDA approves three Takeda diabetes drugs; expands use of Novartis' Gleevec and Pfizer's Prevnar 13
28 January 2013
Research results for Pfizer's Chantix, Pristiq and Toviaz
27 January 2013
Negative NICE final guidance for Pierre Fabre's Javlor in bladder cancer; fast-track FAD for Eliquis
23 January 2013
Good EMA news for Pfizer's Bosulif but not for Santhera's Raxone
21 January 2013
Pfizer's Zoetis spin-off could raise $12 billion; BGI-Shenzhen updates on Complete Genomics deal
20 January 2013
Pfizer's Quillivant XR oral suspension now available in USA; GlaxoSmithKline files BLA for albiglutide
15 January 2013
Patient trust in drugmakers declining, new report shows
14 January 2013
Repligen in $70 million deal with Pfizer for SMA program
4 January 2013
US FDA approves Merck KGaA's Rebif Rebidose
4 January 2013
US FDA finally approves Bristol-Myers/Pfizer's Eliquis for stroke prevention in AF patients
31 December 2013
Japanese approvals for Novo's Ryzodeg, UCB/Otsuka's Neupro and B-MS/Pfizer's Eliquis
27 December 2012
Halozyme Thera in $500 million-plus deal with Pfizer for biologics
24 December 2012
Global rheumatology market controlled by Enbrel, Humira and Remicade
24 December 2012
Brazil's atrial fibrillation market to grow at 31% annually over the next five years
19 December 2012
News briefs: US Crestor patent upheld; Pfizer animal health plans; Teva South Korea JV
17 December 2012
Pfizer agrees $55 million settlement for off-label promotion of Protonix by Wyeth; strikes deal over Zyvox and Lyrica
13 December 2012
Forest launches COPD product Tudorza in USA
12 December 2012
Protalix and Pfizer expand Elelyso agreement
7 December 2012
Insights on the US Alzheimer's disease market
3 December 2012
M&A briefs: BioCryst/Presidio; Pfizer/Nestle; Teva
3 December 2012
Teva to raise stake in Rexahn; Pfizer completes NextWave deal
28 November 2012
Rhythm expands Series B financing to $33 Million, adding Pfizer Ventures as an investor
27 November 2012
Prognosis for renal cell carcinoma market development
27 November 2012
Use of low-molecular-weight heparins and vitamin K antagonists for VTE set for sharp decline as oral agents roll out
21 November 2012
Pfizer's Lyrica misses primary endpoint in seizure frequency trial; positive in fibromyalgia
20 November 2012
Pfizer in $58 million drug discovery accord on cystic fibrosis
19 November 2012
Australia to add Pfizer's Lyrica to PBS list; call for antibiotic research incentives
18 November 2012
Atrial fibrillation drug market will grow from $2.7 billion in 2011 to $9.2 billion in 2021
13 November 2012
Watson gains FDA approval for generic Revatio
12 November 2012
India's Cipla cuts prices of three cancer drugs
12 November 2012
Canada's Supreme Court paves way for generic Viagra
9 November 2012
FDA approves Pfizer's Xeljanz for rheumatoid arthritis
7 November 2012
Bristol-Myers and Pfizer collaborate on Eliquis study with Portola's universal Factor Xa inhibitor antidote PRT4445
5 November 2012
Pfizer 3rd-qtr profits slump on lower than expected sales; EU says "no" to Gaucher drug
2 November 2012
Revised terms for ViiV Healthcare and Shionogi HIV partnership
30 October 2012
Conditional European approval for Pfizer's Xalkori
25 October 2012
Pfizer to buy NextWave Pharma for as much as $680 million
23 October 2012
New LABA/LAMA drugs set to fracture COPD market
10 October 2012
Milestone payments for Epizyme and Antares Pharma
3 October 2012
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
